Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II StudyNaval Daver, Hagop M. Kantarjian, Guillermo Garcia‐Manero et al.|Cancer Discovery|2018Cited by 570
Ibrutinib and Venetoclax for First-Line Treatment of CLLNitin Jain, William G. Wierda, Gautam Borthakur et al.|New England Journal of Medicine|2019Cited by 502
Ph-like acute lymphoblastic leukemia: a high-risk subtype in adultsNitin Jain, Marina Konopleva, Kathryn G. Roberts et al.|Blood|2016Cited by 385
Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomicsKiyomi Morita, Koichi Takahashi, Feng Wang et al.|Nature Communications|2020Cited by 383
Frequency and Spectrum of BRAF Mutations in a Retrospective, Single-Institution Study of 1112 Cases of MelanomaWesley O. Greaves, Rajyalakshmi Luthra, Shalini Verma et al.|Journal of Molecular Diagnostics|2012Cited by 217